| Title: |
Orexin receptors in GtoPdb v.2023.1 |
| Authors: |
Aston-Jones, Gary; Bonaventure, Pascal; Coleman, Paul; de Lecea, Luis; Hartman, Debbie; Hoyer, Daniel; Jacobson, Laura; Kilduff, Thomas; Kukkonen, Jyrki P.; McDonald, Terrence P.; Porter, Rod; Renger, John; Sakurai, Takeshi; Siegel, Jerome M; Sutcliffe, Gregor; Upton, Neil; Winrow, Christopher J.; Yanagisawa, Masashi |
| Source: |
IUPHAR/BPS Guide to Pharmacology CITE; Vol. 2023 No. 1 (2023) ; 2633-1020 |
| Publisher Information: |
University of Edinburgh |
| Publication Year: |
2023 |
| Subject Terms: |
GtoPdb_general: generated Tue May 2 16:06:16 2023; family F51; Orexin receptors; version 2023.1; GtoPdb_hierarchy: ( F51 O321 O322 I51 ); GtoPdb_authors: 1 281 282 283 284 286 452 453 507 508 509 1121 1122 1123 1124 1125 1126 1127; GtoPdb_references: 5596 5597 5599 5600 5601 5602 5603 5604 5606 5608 5609 5610 5611 5612 5613 5614 5615 5616 5617 5618 5619 5620 5621 5622 5623 5624 5625 5626 5627 5628 5629 5631 5632 5633 5634 5635 5637 5638 5639 5640 5642 5643 5644 5645 5646 5647 5649 5650 5651 5653 5654 7022 11446 11447 11448 11449 11450 11451 11452 11453 14359 15210 15233 15238 16448 16449 16450 16451 16452 16453 16454 16455 16456 16457 16458 16459 16460 16461 16462 16463 16464 16465 16466 16467 16468 16473 16474 26557 30881 30882 30883 30916 31577 31578 31579 31580 31581 31582 31583 31584 31585 31586 31588 31589 31590 31591 31592 31593 31594 31595 31596 31598 31600 31605 31608 31617 31722 32275 32276 32277 37264 37266 37269 37271 37278 41386 41387 41539 41540 41541 41542 42159 42598 42701 43287 44768 44769 44770 44771 44772 44773 44774 44839 45001 45002 45007 45009 45032 45429 45431 45432 |
| Description: |
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [117]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant and lemborexant and daridorexant, which are used as hypnotics, and several dual and OX2-selective antagonists are under development. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [146, 144, 55, 126, 47, 109, 7, 145]. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf; text/html |
| Language: |
English |
| Relation: |
https://journals.ed.ac.uk/gtopdb-cite/article/view/8699/11491; https://journals.ed.ac.uk/gtopdb-cite/article/view/8699/11492; https://journals.ed.ac.uk/gtopdb-cite/article/view/8699/11493 |
| DOI: |
10.2218/gtopdb/F51/2023.1 |
| Availability: |
https://journals.ed.ac.uk/gtopdb-cite/article/view/8699; https://doi.org/10.2218/gtopdb/F51/2023.1 |
| Rights: |
Copyright (c) 2023 The authors |
| Accession Number: |
edsbas.A16E702C |
| Database: |
BASE |